X-twitter Youtube Instagram Video

Unlearn.AI

Verified

Unlearn.AI builds digital twins of clinical trial participants to help pharmaceutical companies reduce control group sizes. The platform uses generative AI to predict patient outcomes over 18 to 24 months. However, it currently limits its disease models mostly to neurology and immunology, requiring massive historical datasets to function.
  • Pricing: Custom Pricing
Website

What is Unlearn.AI?

Unlearn.AI generates data for patients who do not exist. Regulatory bodies accept this synthetic data in clinical trials. Researchers use this platform to simulate how real patients respond to a placebo, replacing massive human control groups.

This approach cuts recruitment time by months.

Developed by Unlearn.AI, Inc., this platform targets pharmaceutical companies running Phase 2 and Phase 3 clinical trials. Finding enough human participants for a control arm often delays medical research. Unlearn.AI solves this by creating Prognostic Digital Twins. These machine learning models predict patient outcomes based on baseline health data. The system ingests standard patient metrics and outputs a highly accurate forecast of disease progression.

  • Primary Use Case: Reducing control group sizes in Phase 2 and Phase 3 clinical trials.
  • Ideal For: Pharmaceutical enterprise teams and clinical research organizations.
  • Pricing: Starts at $Custom (Enterprise): No public pricing exists, requiring direct sales negotiations.

Key Features and How Unlearn.AI Works

TwinRCTs and Digital Twins

  • TwinRCTs: Integrates AI-generated digital twins to supplement control arms, limited to specific trial designs.
  • Prognostic Digital Twins: Predicts patient outcomes from baseline data, limited by the quality of historical data provided.
  • Participant Matching: Matches digital twins to actual enrolled patients, limited to baseline characteristics available in the system.

Disease Models and Analysis

  • Disease-Specific Models: Generates models for Alzheimer’s and MS, limited to neurology and immunology fields.
  • Longitudinal Data Analysis: Predicts patient trajectories over 18 to 24 months, limited by the predictability of the specific disease.
  • Simulation Engine: Runs thousands of virtual trial simulations, limited by computing resources and API rate limits.

Compliance and Integration

  • PROCOVA Method: Uses a proprietary statistical method to increase trial power, limited by strict adherence requirements to avoid bias.
  • Regulatory Alignment: Aligns with FDA and EMA qualification frameworks, limited by the need for trial-specific regulatory approval.
  • Data Security: Maintains SOC 2 Type II compliance for sensitive data, limited to standard enterprise security environments.

Unlearn.AI Pros and Cons

Pros

  • Cuts clinical trial costs by decreasing the number of human patients needed for placebo control arms.
  • Accelerates time-to-market for new drugs by shortening the recruitment phase for difficult populations.
  • Provides an ethical advantage by allowing more real participants to receive the active treatment.
  • Holds formal qualification from the EMA and letters of support from the FDA for its methodology.

Cons

  • Presents a high barrier to entry with custom enterprise pricing and complex implementation requirements.
  • Restricts usage primarily to neurology and immunology, offering little support for rare diseases.
  • Requires access to massive historical datasets to train models for new medical indications.

Who Should Use Unlearn.AI?

  • Enterprise Pharmaceutical Companies: Large organizations running Phase 3 trials save millions by reducing control group sizes. The platform integrates directly with their existing Electronic Data Capture systems.
  • Clinical Research Organizations: Teams managing trials for multiple sponsors use the simulation engine. They optimize trial design before patient enrollment begins.
  • Neurology Researchers: Scientists studying Alzheimer’s or MS benefit from the specialized disease models already available on the platform.
  • Solo Researchers and Small Labs: This tool is not a good fit for small academic teams. The custom enterprise pricing and massive data requirements make it inaccessible for low-budget projects.

Unlearn.AI Pricing and Plans

Unlearn.AI does not offer a free tier or a public pricing page. The company operates strictly on a custom enterprise pricing model. Pharmaceutical companies must contact the sales team to negotiate contracts. Pricing depends on the specific clinical trial size, the required disease model, and the duration of the study.

You cannot test the software through a standard free trial.

(This lack of transparent pricing creates friction for teams trying to estimate trial budgets early in the planning phase). Buyers pay for tailored solutions, API access, and regulatory support. The high cost restricts access to well-funded corporate sponsors.

How Unlearn.AI Compares to Alternatives

Similar to Medidata AI, Unlearn.AI focuses on clinical trial optimization. Medidata AI offers a broader suite of clinical data management tools, while Unlearn.AI specializes in generative digital twins for control arms. Medidata AI relies on historical clinical trial data to create synthetic control arms. Unlearn.AI uses its PROCOVA method to predict individual patient trajectories. Medidata AI suits teams needing end-to-end trial management. Unlearn.AI suits teams focused strictly on reducing control group sizes.

Unlike GNS Healthcare, which builds causal AI models to discover new drug targets, Unlearn.AI focuses on the clinical trial execution phase. GNS Healthcare helps researchers understand disease mechanisms. Unlearn.AI helps researchers run faster trials by reducing the need for human placebo participants. Both require massive datasets, but they serve different stages of drug development. GNS Healthcare works best during early preclinical research. Unlearn.AI provides value during Phase 2 and Phase 3 trials.

The Verdict for Clinical Trial Sponsors

Unlearn.AI offers massive value to large pharmaceutical companies running trials in neurology or immunology. If you struggle to recruit patients for Alzheimer’s or MS trials, this platform cuts months off your timeline. The regulatory backing from the EMA and FDA makes it a safe bet for enterprise teams. The PROCOVA statistical framework ensures your trial results remain valid. If you run a small academic lab or research rare diseases outside their current models, look elsewhere. You should consider Medidata AI if you need a broader clinical data management system rather than highly specific digital twins.

Core Capabilities

Key features that define this tool.

  • TwinRCTs: Integrates AI-generated digital twins to supplement control arms, limited to specific trial designs.
  • Prognostic Digital Twins (PDTs): Predicts patient outcomes from baseline data, limited by the quality of historical data provided.
  • Disease-Specific Models: Generates models for Alzheimer’s and MS, limited to neurology and immunology fields.
  • Regulatory Alignment: Aligns with FDA and EMA qualification frameworks, limited by the need for trial-specific regulatory approval.
  • PROCOVA™ Method: Uses a statistical method to increase trial power, limited by strict adherence requirements to avoid bias.
  • Data Security: Maintains SOC 2 Type II compliance for sensitive data, limited to standard enterprise security environments.
  • Simulation Engine: Runs thousands of virtual trial simulations, limited by computing resources and API rate limits.
  • Longitudinal Data Analysis: Predicts patient trajectories over 18 to 24 months, limited by the predictability of the specific disease.
  • Participant Matching: Matches digital twins to actual enrolled patients, limited to baseline characteristics available in the system.

Pricing Plans

  • Enterprise/Custom Plans: Contact for pricing — No free tier available; tailored solutions for clinical trials and digital twins.

Frequently Asked Questions

  • Q: How does Unlearn.AI create digital twins for clinical trials? Unlearn.AI uses generative machine learning models trained on historical patient data. The system inputs baseline health metrics from a real patient to predict their disease progression over 18 to 24 months.
  • Q: Is Unlearn.AI FDA approved for use in Phase 3 trials? Unlearn.AI holds formal qualification from the EMA and letters of support from the FDA. Researchers must still seek specific regulatory approval for each individual clinical trial application.
  • Q: What is the PROCOVA method in clinical research? PROCOVA is a statistical framework developed by Unlearn.AI. It incorporates prognostic scores from digital twins into randomized controlled trials to increase statistical power without introducing bias.
  • Q: How much does Unlearn.AI cost for a pharmaceutical company? Unlearn.AI uses custom enterprise pricing. Costs vary based on the size of the clinical trial and the specific disease model required. The company does not publish standard pricing tiers.
  • Q: Which diseases does Unlearn.AI currently support? The platform focuses on neurology and immunology. It offers specialized generative models for Alzheimer’s disease, Multiple Sclerosis, ALS, and Huntington’s disease.

Tool Information

Developer:

Unlearn.AI, Inc.

Release Year:

2017

Platform:

Web-based

Rating:

4.5